
Alumis Inc (ALMS) Stock Forecast & Price Target
Alumis Inc (ALMS) Analyst Ratings
Bulls say
Alumis is a promising clinical-stage biopharmaceutical company with a strong focus on developing two TYK2 inhibitors for the treatment of Psoriasis and other immune-mediated diseases. While there is some risk in terms of market entry and pricing, the company's pipeline and potential for peak sales of $3.4 billion in 2035 demonstrate strong growth potential. In addition, the company's strategy of potentially developing a QD formulation in the future could help it better compete in a market dominated by QD options.
Bears say
Alumis is currently a clinical-stage biopharmaceutical company with a focus on developing two TYK2 inhibitors for the treatment of autoimmune and neurodegenerative diseases. However, there are significant risks to achieving their target price, including competition from other therapies and potential commercialization challenges. Additionally, the company needs to prove the efficacy and safety of their products in various indications in order to successfully enter the market and justify a premium position. However, the potential market size for their products and their current financials give them a positive outlook, and a successful phase II SLE data readout in 3Q26 could lead to further upside.
This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.
Alumis Inc (ALMS) Analyst Forecast & Price Prediction
Start investing in Alumis Inc (ALMS)
Order type
Buy in
Order amount
Est. shares
0 shares